TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05242094

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation Program
Description: An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation Program
Description: An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
Study: NCT05385484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receives mobile banking account with incentives to save
Description: Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
Study: NCT05856097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping with diaphragmatic breathing
Description: .kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping without diaphragmatic breathing
Description: kinesio tape was applied day 1st of intervention. 3 sessions were given
Study: NCT05792267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence system
Description: Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
Study: NCT06204653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNO group
Description: 100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MV group
Description: Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
Study: NCT05069753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate sequential bilateral cataract surgery (ISBCS)
Description: Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed sequential bilateral cataract surgery (DSBCS)
Description: The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
Study: NCT04886947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
Study: NCT05688891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: 5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings.
Study: NCT04898582

Intervention type: OTHER
Group type: OTHER
Intervention: Mineral 89 Probiotic Fractions
Description: The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
Study: NCT05953909

Intervention type: DRUG
Intervention: Eribulin-Based Regimen
Description: Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.

Intervention type: DRUG
Intervention: Eribulin-Based Regimen
Description: Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.

Intervention type: DRUG
Intervention: Eribulin-Based Regimen
Description: Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.

Intervention type: DRUG
Intervention: nab-paclitaxel based regimen
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.

Intervention type: DRUG
Intervention: nab-paclitaxel based regimen
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.

Intervention type: DRUG
Intervention: nab-paclitaxel based regimen
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.

Intervention type: DRUG
Intervention: Other Chemotherapy Regimen
Description: TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)

Intervention type: DRUG
Intervention: Other Chemotherapy Regimen
Description: TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)

Intervention type: DRUG
Intervention: Other Chemotherapy Regimen
Description: TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)
Study: NCT06510985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiowatch bracelet
Description: The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiowatch bracelet
Description: The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
Study: NCT06058130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Oral
Description: Anticoagulation alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation combined with antiplatelet therapy
Description: Anticoagulation combined with antiplatelet therapy
Study: NCT05013268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin
Description: * Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none
Study: NCT04835168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11 low
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11 high
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT05858957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 100 ml saline infusion apply to the Group S
Study: NCT06255067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride with noisome carrier
Description: patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline Hydrochloride only
Description: patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
Study: NCT05205655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collection of odour samples
Description: Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: collection of odour samples
Description: Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
Study: NCT06258057

Intervention type: OTHER
Intervention: Not applicable / database analysis
Description: Not applicable / database analysis

Intervention type: OTHER
Intervention: Not applicable / database analysis
Description: Not applicable / database analysis
Study: NCT05595681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
Description: The investigational product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO.
Study: NCT05837858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain-wheat flour food+standardized meals
Description: whole grain food made by 50 g whole grain wheat flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain-wheat flour food+standardized meals
Description: whole grain food made by 50 g whole grain wheat flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined wheat flour food+standardized meals
Description: refined grain food made by 50 g refined wheat flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined wheat flour food+standardized meals
Description: refined grain food made by 50 g refined wheat flour
Study: NCT06198088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF techniques
Description: The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise therapy
Description: exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
Study: NCT06105294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time-restricted eating
Description: Restrict eating to a 10-hour window.
Study: NCT06318611

Intervention type: OTHER
Intervention: sleep, chronotype
Description: Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.

Intervention type: OTHER
Intervention: sleep, chronotype
Description: Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
Study: NCT05860491

Intervention type: OTHER
Intervention: dietary fiber
Description: Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia

Intervention type: OTHER
Intervention: dietary fiber
Description: Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
Study: NCT06506799

Intervention type: OTHER
Group type: OTHER
Intervention: Training Given to Intensive Care Nurses on the Use of Physical Fixation
Description: Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test.
Study: NCT04220008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT06632548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telescopic overdenture
Description: two implant retained mandibular overdenture with telescopic attachment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telescopic overdenture
Description: two implant retained mandibular overdenture with telescopic attachment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: telescopic overdenture
Description: two implant retained mandibular overdenture with telescopic attachment
Study: NCT04536376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Program
Description: Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.
Study: NCT06361719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Description: Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
Study: NCT05026827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: Participation in Iyengar Yoga classes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Socialization Control
Description: Participation in socialization control group sessions
Study: NCT04909229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-003b PDT Intervention
Description: The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fitbit
Description: Patients will receive a Fitbit and receive standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Patients will receive a Fitbit and receive standard of care

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep education materials
Description: Patients will receive sleep hygiene and healthy sleep tips.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep education materials
Description: Patients will receive sleep hygiene and healthy sleep tips.
Study: NCT06581887

Intervention type: BEHAVIORAL
Intervention: Classical conditioning task
Description: To evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD/BMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural/emotional characteristics of the syndrome.
Study: NCT06582667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: US guided PENG block in hip fracture without anti thrombotic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: US guided PENG block in hip fracture without anti thrombotic therapy
Study: NCT05776823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Narcan Training
Description: A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIRT
Description: BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMC
Description: SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Counselor Narcan Training
Description: A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.